tbuckley/cabot-search huggingface dataset:
SP0191 Sexual Health in Rheumatoid Arthritis - The Role of The Physiotherapist To Enhance Sexual Health
Authors: K. Areskoug Josefsson
Journal: Annals of the Rheumatic Diseases (2016)

Sexual health is often negatively affected by rheumatoid arthritis (RA), but rarely discussed between patients and health care professionals. Experienced reasons for decreased sexual health vary among patients, but pain, stiffness, reduced mobility, fatigue and negative feelings towards one9s own body are common factors. In addition to negative effects experienced to be due to RA, there are also negative influences on sexual health by other factors, such as insufficient physical activity, low self-esteem, depression and stressful influences in life. Physiotherapy is a common intervention for patients with RA and patients have reported improved sexual health due to physiotherapy. Regular physiotherapy interventions for patients with RA often include coaching towards increasing physical activity levels, hydrotherapy, pain reductive treatment and mobility exercises, both individually and in groups. The physiotherapy interventions leading to improved sexual health (according to patients with RA) has been regular interventions for patients with RA and not specifically aimed at enhancing sexual health. The patients do seldom describe that the physiotherapist has informed them of how physiotherapy might enhance sexual health, but they have themselves experienced how physiotherapy has improved their sexual life. Patients describe that they experience joy, increased self-esteem and a more positive approach to their body, when participating in physiotherapy and that this positive feeling is affecting their life, including their sexual life. They also describe how increased physical capacity reduces fatigue and increases their capacity to engage in valued life activities, including sexual activities. The way that the physiotherapist can further enhance sexual health, is by informing the patient of how sexual health is linked to experienced symptoms of RA and how physiotherapy interventions, for example increasing physical activity, can enhance also sexual health. <h3>Disclosure of Interest</h3> None declared
AB0723 The Clinical Assessment of Anti-Cyclic Citrullinated Peptide Antibodies in Psoriatic Arthritis: Table 1.
Authors: O. Ozdemir Isik, F. Cosan, A. Yazici, A. Cefle
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Psoriatic arthritis (PsA) is a chronic inflammatory disease in the spondyloarthropathy group with the history of psoriasis. Although some PsA findings are similar to rheumatoid arthritis (RA), RF negativity, some radiological and clinical findings are different in PsA. There is no spesific laboratory examination for diagnosis of PsA. On the other hand, anti-CCP antibody positivity is a spesific finding for the diagnosis of RA. <h3>Objectives</h3> We aimed in this study to analyse the frequency of anti-CCP positivity in PsA and the assciaton with clinical and radiological findings. <h3>Methods</h3> The study group is consisted of 100 PsA patients, who fulfilled the CASPAR cirteria for PsA and 100 healthy controls (HC). We filled a form for all patients, which included clinical and laboratory findings of patients. We analyzed anti-CCP antibody with microELISA in the sera of patients. <h3>Results</h3> In our study, the anti-CCP positivity (40,9±63,5 IU/ml) was detected in 15% of PsA group and 4% of healthy controls. The difference was statistically significant (p=0,014; OR=4.24, 95% CI=1.35–13.25).Nine out of 15 anti-CCP positive patients were female, the remaining 6 were male. Thirteen patients (86,7%) had peripheral arthritis, 1 patient (6,7%)had sacroiliitis, 1 patient (6,7%) had peripheral arthritis and sacroiliitis. 42,8% of PsA patients with peripheral arthritis had asymetric olygoarthritis (6/14), 28,5% had monoarthritis (4/14) and 28,5% had symetric polyarthritis (4/14). Anti-CCP antibody positivity had no effect on the involvement of peripheral arthritis. Sacroiliitis and dactilitis were more frequent in the anti-CCP negative group. No patient with dactylitis had anti-CCP positivity (p=0.005). While, 43,5% of RF positive patients were detected anti-CCP positivity, 6,5% of RF negative patients were detected anti-CCP positivity (p=0,000). <h3>Conclusions</h3> Our data reveals that anti-CCP positivity is more frequent in PsA compared to HC. We found no statisticall association between anti-CCP positivity and clinical or radiological findings. <h3>References</h3> Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68:1387–94. Ritchlin CT, Haas-Smith SA, Li P, et al. Mechanisms of TNF- alpha and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003;111(6):821–31. <h3>Disclosure of Interest</h3> None declared
Brentuximab Vedotin Demonstrates Significant Clinical Activity in Relapsed or Refractory Mycosis Fungoides with Variable CD30 Expression
Authors: Michael Krathen, Uma Sundram, Sameer Bashey, Katherine Sutherland, Katrin Salva, Gary S Wood, Ranjana H. Advani, Richard T. Hoppe, Sunil Reddy, Randall Armstrong, Seema Nagpal, Melissa Pulitzer, Steven M. Horwitz, Youn H. Kim
Journal: Blood (2012)
SAT0275 Kawasaki Disease – An Eastern Indian Cohort of 7years
Authors: P.P. Giri, P. Pal
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Kawasaki disease (KD), an acute febrile childhood vasculitis can present with varying clinical features and the main complication is involvement of coronary arteries (1). The epidemiological pattern may be different in different geographical regions, even it can vary within a country. KD is not unusual in India but published series are infrequent (2). Here we present a series of 185 cases of KD diagnosed in our hospital in last 7 years to have a look in to the varied clinical manifestations, epidemiology, atypical features and complications. <h3>Objectives</h3> 1. To analyse the record of Kawasaki disease diagnosed in the study period. 2. Compare the epidemiology and clinical features of KD in our part of the country with that of the published series from northern India. 3. To note the atypical features and estimate the incidence of coronary involvement. <h3>Methods</h3> Clinical records of 185 children fulfilling the diagnostic criteria of Kawasaki Disease and admitted at the Institute of Child Health, Kolkata during the time period October 2008 to January 2016 were reviewed. The data collected included details of clinical and laboratory features, treatment and outcome. <h3>Results</h3> A total of 185 patients were diagnosed as KD (4.8 per 1000 hospital admission). Among these 185 patients,171 presented with typical features of KD, rest 14 were atypical including KD with erythroderma, KD with bilateral ptosis, neonatal KD, KD with facial Palsy,KD with nephrotic syndrome etc. Average age of presentation was 22 months. Most patients presented with fever of an average duration of 9 days. Besides the typical features, we want to stress upon some special features of KD, like orange-brown chromonychia (orange brown discolouration of nails) in 65% of cases, BCG scar reactivation in 14%, extreme irritability in 86% and greenish loose stools in about 68%. Echocardiographic abnormalities (ectasia or aneurysm) were detected in 29% of cases. All patients received Intravenous Immunoglobulin of which 7 did not respond to a single dose of 2gram/kg. <h3>Conclusions</h3> 1. A bimodal seasonality has been seen with clustering of cases during March- April and September-October. 2. Mean age of onset (22 months) is lower than the north India series. 3. Most (94%) presented with typical form with a response rate of 96% with first dose ivIg. 4. Orange brown Chromonychia is a novel finding that has been seen in a significant number of patients. 5. Coronary abnormalities is on the higher side than the reported series from north India as well as other parts of the world. <h3>References</h3> Kawasaki T. General review and problems in Kawasaki disease. Jpn Heart J 1995; 36: 1–12. Singh S, Bansal A, Gupta A, Manojkumar R, Mittal BR. Kawasaki Disease – a decade of experience from North India. Int Heart J 2005; 46: 679–689. <h3>Acknowledgement</h3> 1.Dr. Apurba Ghosh <h3>Disclosure of Interest</h3> None declared
Patient Age Predicts the Delay before Survivors of Cancer Utilise Their Cryopreserved Sperm for Assisted Reproductive Technology
Authors: Amit Patel, Thomas Stroud, Danielle Breen, Ala Taifoor, Anne Bradshaw, Richard Szydlo, Jonathan WA Ramsay, Stephen R Bloom, Waljit S Dhillo, Channa N Jayasena
Journal: Blood (2015)
Blockage of Wnt/B-Catenin Signaling By Nanoparticles Reduces Survival and Proliferation of CLL Cells in Vitro
Authors: Ida Franiak-Pietryga, Henryk Maciejewski, Barbara Ziemba, Dietmar Appelhans, Brigitte Voit, Malgorzata Misiewicz, Tadeusz Robak, Jacek Trelinski, Maria Bryszewska, Maciej Borowiec
Journal: Blood (2015)
David Alexander Anderson Primrose
Authors: Willie Primrose
Journal: BMJ (2016)

David Alexander Anderson Primrose initially took on university training in accountancy and law and was attached to the accountancy firm Peat, Marwick and Mitchell. The war intervened, however, and he spent almost six years with the Eighth Army, mostly in Egypt, Libya, and Italy. On his return to Glasgow he completed his earlier studies, graduating in 1947, and started as a medical student, graduating in 1951. Law, accountancy, and medicine were a unique combination that was to prove useful in later years.

In 1950 he married a fellow doctor, Marjory Snodgrass, who also came also from a medical family. One of David’s initial publications was a joint paper with his new wife, relating to the role of radioactive phosphorus in the …
Thalidomide (T) in Combination with Fludarabine (F) as Initial Therapy for Patients (pts) with Treatment Naïve Chronic Lymphocytic Leukemia (CLL): Preliminary Results of a Phase I/II Clinical Trial.
Authors: Asher Alban Chanan-Khan, Kena C. Miller, Patricia Marshall, Swaminathan Padmanabhan, William Brady, Zale P. Bernstein, Paul Wallace, Myron S. Czuczman
Journal: Blood (2005)
STEM-04DEFINING GLIOBLASTOMA STEM CELL HETEROGENEITY
Authors: N. Sumru Bayin, Rajeev Sen, Sheng Si, Aram S. Modrek, Valerio Ortenzi, David Zagzag, Matija Snuderl, John G. Golfinos, Werner Doyle, Nataliya Galifianakis, Mitch Chesler, Irineu Illa-Bochaca, Mary Helen Barcellos-Hoff, Igor Dolgalev, Adriana Heguy, Dimitris Placantonakis
Journal: Neuro-Oncology (2015)

A major impeding factor in designing effective therapies against glioblastoma (GBM) is its extensive molecular heterogeneity and the diversity of microenvironmental conditions within any given tumor.To test whether Overall survival
High-Density Genomic Scan with 50k SNP Arrays May Reveal Existence of Germline Allelic Polymorphisms That Determine Predisposition to Aplastic Anemia.
Authors: Marcin W. Wlodarski, Lukasz Gondek, Debora Poruban, Martina Veigl, Matt Kalaycio, Jaroslaw P. Maciejewski
Journal: Blood (2005)
TMIC-18TUMOR-ASSOCIATED MICROGLIA/MACROPHAGES ARE ASSOCIATED WITH POOR PROGNOSIS IN HIGH-GRADE GLIOMAS AND CONTRIBUTE TO THE GLIOBLASTOMA STEM CELL-LIKE NICHES
Authors: Mia Dahl Sørensen, Rikke Hedegaard Dahlrot, Steinbjørn Hansen, Bjarne Winther Kristensen
Journal: Neuro-Oncology (2015)
MK-0457, a Novel Multikinase Inhibitor, Inhibits BCR-ABL Activity in Patients with Chronic Myeloid Leukemia (CML) and Acute Lymphocytic Leukemia (ALL) with the T315I BCR-ABL Mutation.
Authors: Donald A. Bergstrom, Jason B. Clark, Alan Xiao, Matthew Griffiths, Susannah Falcon, John Pollard, Steven J. Freedman, Francis Giles
Journal: Blood (2006)
Antioxidative/preventive capacity of a flavonoid/polyphenolic rich fruit juice reducing oxidative cell damage in healthy probands
Authors: Christine Janzowski, Tamara Weisel, Elena Leonhardt, Matthias Baum, Helmut Dietrich, Frank Will, Gerhard Eisenbrand
Journal: Cancer Research (2005)

Proc Amer Assoc Cancer Res, Volume 46, 2005

774 

Oxidative cell damage is associated with the pathogenesis of cancer and other diseases. An imbalance between pro- und antioxidative processes has also been described in the course of chronic diseases. Increased uptake of food based antioxidants via fruit juice with high flavonoid/polyphenol content, resulting from selected fruit varieties and technological processing, is a promising preventive measure to reduce oxidative cell damage and stress response. An intervention study was performed with a red mixed fruit juice (0.7l/day; 18 healthy subjects, age 20-40 years, non-smokers). After a three week run-in period, the participants daily consumed 700ml of the juice (red grape, blackberry, sour cherry, black currant, black chokeberry; TEAC 19.1 mmol/l trolox) in a four week intervention, followed by a three week wash-out period. Sampling of venous blood was performed once a week to analyse oxidative DNA damage (comet assay with/without formamidopyrimidine-DNA-glycosylase). Lipid peroxidation was monitored fluorimetrically as thiobarbituric acid reactive substances and by HPLC/fluorescence of the respective malondialdehyde derivative in plasma. Glutathione (total glutathione, tGSH; oxidised glutathione, GSSG; glutathione status: reduced glutathione, GSH in % of tGSH) was determined in whole blood with a kinetic photometric assay. DNA binding activity of the transcription factor NfκB was measured in primary blood mononuclear cells by an immunosorbent assay (ELISA). The results show a decrease of oxidative DNA damage during the intervention, reflected by mean tail intensities of 2.5-3 TI% in the run-in phase and 1-1.3 TI% in the juice-uptake phase (p<0.0005, one sided paired t-test). Further, an increase of reduced glutathione (p<0.0005) and of glutathione status (p<0.05) was observed. In the subsequent wash-out phase oxidative DNA damage and glutathione approached the run-in levels. Additionally, the results indicate a decrease of the NfκB-DNA binding activity in the intervention period, followed by a reincrease in the wash-out phase. A significant juice dependant reduction of lipid peroxidation was not observed. In conclusion, the flavonoid/polyphenolic rich red fruit juice clearly shows a potential to reduce oxidative cell damage in healthy probands (Support: DFG grant no. BA 2241/1-1).
Low-Dose Total Body Irradiation (TBI) and Fludarabine Conditioning for Hematopoietic Cell Transplantation (HCT) in Patients with HLA-Class I Mismatched Donors.
Authors: Hirohisa Nakamae, Barry Storer, Thomas Chauncey, Michael Pulsipher, Finn Petersen, James C. Wade, Michael Maris, Ben Bruno, Effie Petersdorf, David Maloney, Rainer Storb, Brenda M. Sandmaier
Journal: Blood (2007)
A Close Association of History of Autoimmunity with Chronic Myelomonocytic Leukemia (CMML) in Contrast to Chronic Myelogenous Leukemia (CML)
Authors: Deniz Peker, Eric Padron, Pedro Horna, John M. Bennett, Xiaohui Zhang, P.K. Epling-Burnette, Jeffrey E Lancet, Javier Pinilla, Lynn Moscinski, Alan F. List, Rami S. Komrokji, Ling Zhang
Journal: Blood (2012)
Prediction of Overall Survival in 520 Patients with Primary Myelofibrosis: Outcome Update of the Dynamic International Prognostic Scoring System (DIPSS) Patient Cohort
Authors: Margherita Maffioli, Elisa Rumi, Francisco Cervantes, Alessandro M. Vannucchi, Enrica Morra, Cristiana Pascutto, Mario Cazzola, Ayalew Tefferi, Francesco Passamonti
Journal: Blood (2012)
A Novel and Quantitative Assay To Detect JAK2 V617F Allele by Real-Time AS-PCR and Its Applicability to PV Initiating Mutation.
Authors: Roberto H. Nussenzveig, Sabina Swierczek, Jaroslav Jelinek, Srdan Verstovsek, Jaroslav Prchal, Josef T. Prchal
Journal: Blood (2006)
Mutated Nucleophosmin 1 (NPM1) Is an Immunogenic Target and Patients with NPM1mut Acute Myeloid Leukemia (AML) Showed High Expression of Different Leukemia-Associated Antigens (LAAs)
Authors: Susanne Hofmann, Vanessa Schneider, Lars Bullinger, Yoko Ono, Anita Schmitt, Lu Zhang, Marlies Götz, Konstanze Döhner, Joannis Mytilineos, Markus Wiesneth, Hartmut Döhner, Michael Schmitt, Jochen Greiner
Journal: Blood (2012)
Are There Specific Markers in Allografted Patients Blood Predicting GvHD?
Authors: Stéphane Ducassou, Thomas Lavaux, Michele Legrain, Anne- Claire Voegeli, Aurelia Nguyen, Nadine Cojean, Bruno Lioure, Karin Bilger, Raoul Herbrecht, Patrick Lutz, Natacha Entz- Werle
Journal: Blood (2008)
Efficacy and Safety Of Melphalan and Prednisone In Combination With Thalidomide, Bortezomib Or Lenalidomide In Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients: A Single Center Experience
Authors: Fabiana Gentilini, Vincenzo Federico, Eleonora Russo, Paola Finsinger, Roberto Ricci, Patrizia Del Bianco, Francesca Prestanicola, Moira Cappelloni, Maria Letizia Vallone, Robin Foa, Maria Teresa Petrucci
Journal: Blood (2013)
Targeting the Osteoblast in Myelodysplasia and Acute Myeloid Leukemia
Authors: Masahiro Marshall Nakagawa, Aruna Kode, Sanil J Manavalan, Govind Bhagat, Julie Teruya-Feldstein, Azra Raza, Ellin Berman, Stavroula Kousteni
Journal: Blood (2015)
EXEL-8232, a Small Molecule JAK2 Inhibitor, Effectively Treats Thrombocytosis and Extramedullary Hematopoiesis in a Murine Model of Myeloproliferative Disease Induced by MPLW515L
Authors: Gerlinde Wernig, Michael G. Kharas, Dena S. Leeman, Rachel Okabe, Maricel Gozo, Mahnaz Paktinat, Erika Haydu, Brian Ball, Tulasi Khandan, Douglas O. Clary, D Gary Gilliland
Journal: Blood (2008)
Assessment of Cardiovascular Events in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors
Authors: Katia B.B. Pagnano, Paola Morelato Assunção, Roberto Zullli, Marcia T Delamain, Gislaine OLIVEIRA Duarte, Irene Lorand-Metze, Carmino A De Souza
Journal: Blood (2015)
Targeting Leukemia Initiating Cells by MUC1-C Subunit Inhibition
Authors: Dina Stroopinsky, Jacalyn Rosenblatt, Heidi Mills, Caterina Nardella, Keisuke Ito, Li Yin, Hasan Rajabi, Baldev Vasir, Turner Kufe, Katarina Luptakova, Jon E. Arnason, James D. Levine, Robin Joyce, Dimitrios Tzachanis, Vassiliki A. Boussiotis, Ilene Galinsky, Richard M. Stone, Yoram Reiter, Pier Paolo Pandolfi, Donald Kufe, David Avigan
Journal: Blood (2012)
Lack of IL-21 Signal Attenuates Graft-Versus-Leukemia Effect In the Absence of CD8 T-Cells.
Authors: Katsutoshi Ozaki, Akiko Meguro, Keiko Hatanaka, Iekuni Oh, Haruko Matsu, Raine Tatara, Kazuya Sato, Warren J Leonard, Keiya Ozawa
Journal: Blood (2010)
AB0466 Damage Index in Patients with Thrombotic Antiphospholipid Syndrome: Retrospective Cohort Study
Authors: L.A. Martinez-Martinez, M.J.N.N. Chacon-Perez, M.C. Amigo
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The antiphospholipid syndrome is an autoimmune-acquired thrombophilia, the thrombotic manifestations are associated with an important risk of organ damage.<sup>1</sup> A new index for assessment of thrombotic accumulative damage in APS has been proposed, it is called <i>Damage Index in patients with Thrombotic Antiphospholipid Syndrome</i> (DIAPS).<sup>2</sup> <h3>Objectives</h3> Explore the DIAPS change in patients with primary and secondary APS in a long-term retrospective cohort. <h3>Methods</h3> Clinical records of patients with APS according to the Sapporo<sup>3</sup> classification criteria and/or Sydney<sup>4</sup> were reviewed. The DIAPS instrument with 38 items was applied. Comparison of the initial and final DIAPS was performed using the Wilcoxon test and the changes in the follow up were analyzed with T Student. The main treatments were analyzed before and after with the NcNemar test. <h3>Results</h3> Fifty clinical charts were reviewed, 12 had to be excluded for not fulfill classification criteria or incomplete information. Initial and final DIAPS was recorded in 38 patients (13±5 years of follow up), 78.9% were female, with a mean age at diagnosis 44.2±12.4 years. A total of 57.9% had primary APS. Thirty four patients remain alive with 3 to 23 years of follow up. The initial DIAPS was 3±2 and the final score was 5±3 (<i>p</i> &lt;0.0001). The magnitude of change in the DIAPS was similar in primary and secondary APS (<i>p</i> =0.243). During follow up, 31/38 patients had oral anticoagulation at the beginning and 33/35 at the end (<i>p</i> =0.687). At the beginning of the study hydroxychloroquine was recorded in 14/38 patients and in 24/38 at the end (<i>p</i> =0.021). Aspirin was used by 17/38 patients during the follow up (<i>p</i> =1.000). <h3>Conclusions</h3> The change in DIAPS suggests cumulative damage in patients with APS despite treatment. The DIAPS is a useful tool to estimate accrued damage in patients with primary and secondary APS. <h3>References</h3> Grika EP, Ziakas PD, Zintzaras E, et al. Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome. J Rheumatol. 2012;39(3):516–23. Amigo MC, Goycochea-Robles MV, Espinosa-Cuervo G, et al. Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome. Lupus. 2015 Aug; 24(9):927–34. Wilson WA, Gharavi AE, Koike T, et al. International Consensus Statement on Preliminary Classification Criteria for Definite Antiphospholipid Syndrome: Report of an International Workshop. Arthritis Rheum 1999;42(7): 1309–11. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295–306. <h3>Disclosure of Interest</h3> None declared
MTR-13EVALUATION OF p75 EXPRESSION AND PATTERNS OF RECURRENCE IN PATIENTS WITH MALIGNANT GLIOMAS TREATED WITH BEVACIZUMAB
Authors: Gloria Roldan Urgoiti, Sam Lawn, James Scott, Jacob Easaw, Rajappa Kenchappa, Jennie Taylor, Nina Paleologos, David Schiff, Jennifer Chan, Peter Forsyth
Journal: Neuro-Oncology (2015)

BACKGROUND: There is no standard treatment for patients with recurrent malignant gliomas (MGs) and after antiangiogenic therapy, 15% recur in a distant location suggesting the development of VEGF independent invasive mechanisms. We hypothesized that p75NTR expression could be associated to the pattern of recurrence/progression in patients with MGs treated with bevacizumab. METHODS: Adult patients with MGs (gliomas Grade III and Glioblastoma) treated with bevacizumab who had given written consent were identified. Clinical data were extracted from the charts. Pathology was centrally reviewed by a neuropathologist (JC) who also evaluated p75NTR by immunohistochemistry using a scoring system (intensity index, prevalence index - % of positive cells- and a combination index - the product of the two). Brain MRIs underwent central neuroradiology review (JS). All researchers were blinded to others' results. RESULTS: Thirty patients were included; 83% were male; 87% had glioblastoma and 84% received bevacizumab as second line therapy. Recurrences were 42% local (n = 10), 21% diffuse (n= 5) and 12% distal (n = 3). Six patients (25%) had radiologic stability despite clinical deterioration. There was no association between p75 expression and pattern of progression. In univariate analysis, progression free survival (PFS) was associated with KPS [HR 0.94 (CI 95% 0.89–0.990; p = 0.046], prevalence index for p75 [HR 1.8 (CI 95% 1.17-1.34); p = 0.007], and combined score for p75 expression [HR 1.18 (CI 95% 1.03-1.34); p = 0.012]. Patients with >50% p75 positive cells had shorter PFS [HR 3.3 (CI 95% 1.12-8.89); p = 0.018]. Tumors with any p75 positive cell had worse PFS than p75 negative tumors [HR 3.64 (CI 95% 1.18-11.22); p = 0.024]. CONCLUSION: The expression of p75 was associated with PFS in recurrent MGs. We were not able to find an association between the pattern of recurrence/progression and the expression of p75 in patients with MGs after treatment with Bevacizumab.